Mod­er­na files RSV vac­cine for old­er adults in US and Eu­rope

Mod­er­na said Wednes­day that it start­ed a rolling sub­mis­sion to the FDA for its RSV vac­cine in adults 60 years and old­er as it aims to take on Pfiz­er and GSK in what is ex­pect­ed to be a multi­bil­lion-dol­lar mar­ket.

Mod­er­na al­so said it filed for reg­u­la­to­ry re­view of its RSV vac­cine hope­ful in Aus­tralia, Eu­rope, and Switzer­land.

In a news re­lease, the com­pa­ny said it based its sub­mis­sions on an in­ter­im analy­sis from an on­go­ing piv­otal RSV tri­al, known as Con­querRSV. Mod­er­na had ini­tial­ly re­port­ed the win in Jan­u­ary, when the can­di­date, mR­NA-1345, met both of its pri­ma­ry ef­fi­ca­cy end­points — de­fined by ei­ther at least two symp­toms of RSV-as­so­ci­at­ed low­er res­pi­ra­to­ry tract dis­ease or at least three symp­toms of the dis­ease. The biotech said then the vac­cine showed 83.7% ef­fi­ca­cy in the two-symp­toms group and 82.4% in the three-symp­toms group.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER